StonvexLoading…
StonvexStonvexStonvexCore line items from MCY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-27 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.58B | $8.40M | $29.60M | $21.60M | $13.90M |
Operating Income | Not available | $235.65M | $663.65M | $414.77M | $64.45M |
Net Income | Not available | $190.42M | $541.09M | $338.55M | $58.15M |
EPS (Diluted) | $2.20 | $3.44 | $9.77 | $6.11 | $1.05 |
Total Assets | Not available | $9.87B | $9.56B | $9.37B | $9.08B |
Total Liabilities | Not available | $7.28B | $7.14B | $7.14B | $7.11B |
Cash & Equivalents | Not available | $1.35B | $1.32B | $1.25B | $1.12B |
Free Cash Flow OCF − CapEx | Not available | $308.80M | $1.03B | $754.90M | $275.36M |
Shares Outstanding | Not available | 55.39M | 55.39M | 55.39M | 55.39M |